After applying this filtering process, we observed three CRC targets (VEGFA, EGFR, and PTGS2) and five targets that had undergone one or more phase IV trials in any indication (TP53, VEGFA, EGFR, ESR1, and PTGS2) were all found in the top 15 results from this list (Table 4). This evidence concerns the gene TP53 and colorectal carcinoma.